Knowledge Hub

Critical Limb Ischemia - Pipeline Review, H2 2016

Press release   •   Nov 30, 2016 04:53 EST has recently announced the addition of a market study “ Critical Limb Ischemia - Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.

Critical Limb Ischemia - Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia Pipeline Review, H2 2016, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 11, 4, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Critical Limb Ischemia.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Download The sample Copy Of This Report:


- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Content

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Critical Limb Ischemia Overview 10

Therapeutics Development 11

Pipeline Products for Critical Limb Ischemia - Overview 11

Pipeline Products for Critical Limb Ischemia - Comparative Analysis 12

Critical Limb Ischemia - Therapeutics under Development by Companies 13

Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 15

Critical Limb Ischemia - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Critical Limb Ischemia - Products under Development by Companies 19

Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21

Critical Limb Ischemia - Companies Involved in Therapeutics Development 22

AnGes MG, Inc. 22

Apceth GmbH & Co. KG 23

Athersys, Inc. 24

BiogenCell Ltd. 25

Caladrius Biosciences Inc 26

Cynata Therapeutics Limited 27

Hemostemix Ltd 28

Histocell S.L. 29

ID Pharma Co., Ltd. 30

Integene International Holdings LLC 31

Juventas Therapeutics, Inc. 32

Kasiak Research Private Limited 33

Kowa Company, Ltd. 34

Neurofx, Inc. 35

Pharmicell Co., Ltd. 36

Pluristem Therapeutics Inc. 37

ReNeuron Group Plc 38

Symic Biomedical, Inc. 39

Targazyme, Inc. 40

TikoMed AB 41

U.S. Stem Cell, Inc. 42

Vericel Corporation 43

VESSL Therapeutics Ltd 44

ViroMed Co Ltd 45

Critical Limb Ischemia - Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Target 47

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55